Sign In
Buy LUMO
$4.34
+0 (+0%)
At Close: Mar 10, 2025
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround
11:32am, Wednesday, 24'th Nov 2021
Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
Lumos Pharma to Participate in Upcoming Investor Conferences
05:06pm, Wednesday, 10'th Nov 2021
AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company wil
Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know
12:18pm, Monday, 08'th Nov 2021
The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2021 Results - Earnings Call Transcript
10:58pm, Wednesday, 03'rd Nov 2021
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2021 Results - Earnings Call Transcript
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
04:05pm, Thursday, 21'st Oct 2021
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2021 Results - Earnings Call Transcript
05:15pm, Thursday, 05'th Aug 2021
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2021 Results - Earnings Call Transcript
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D.,
Lumos Pharma Delays Data Readout From Pediatric Growth Hormone Deficiency Trial To 2H Of 2023
07:03am, Wednesday, 21'st Jul 2021
Lumos Pharma Inc (NASDAQ: LUMO) expects 6-month primary outcome data from Phase 2 OraGrowtH210 Trial of LUM-201 in the 2H of 2023, citing the pace of site initiation and slower than anticipated en
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q1 2021 Results - Earnings Call Transcript
11:10pm, Wednesday, 05'th May 2021
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q1 2021 Results - Earnings Call Transcript
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
09:00am, Wednesday, 28'th Apr 2021
AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report
Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency
04:05pm, Wednesday, 14'th Apr 2021
Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET
Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues Data show greater GH response in pediatric growth hormone deficiency (PGHD) from
3 Net Current Asset Value Stocks
12:20pm, Friday, 19'th Mar 2021
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reass
Lumos Pharma to Participate in March 2021 Investor Conferences
04:05pm, Thursday, 11'th Mar 2021
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is
Lumos Pharma's (LUMO) CEO Rick Hawkins on Q4 2020 Results - Earnings Call Transcript
05:59am, Wednesday, 10'th Mar 2021
Lumos Pharma's (LUMO) CEO Rick Hawkins on Q4 2020 Results - Earnings Call Transcript
